Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the Pharma & Biotech edition of the IP Thinktank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: http://thinkipstrategy.com/subscribe/

Highlights this week included:

Mircera (Methoxy polyethylene glycol-epoetin beta) – US: Trial judge grants permanent injunction in case relating to recombinant erythropoietin (EPO) patent: Amgen v F Hoffmann-LaRoche: (Hal Wegner) (Holman’s Biotech IP Blog) (Patent Docs) (Patent Docs) (Law360)

Rilutek (Riluzole) – US: Prior art must enable a skilled artisan to make the invention without undue experimentation: Impax Labs v Aventis Pharmaceuticals (Patent Docs) (Hal Wegner) (Patent Prospector) (Law360) (Patently-O)

 

Pharma & Biotech

Pharma & Biotech – General

Pharmaceutical IP management and strategy (IP Think Tank)

Global access to medicines not improved by TRIPS waiver, some say (Intellectual Property Watch)

Biotech, pharma industries to target IP protection legislation, patent reform (Intellectual Property Watch)

International Expert Group on Biotechnology, Innovation and Intellectual Property releases ‘Toward a New Era of Intellectual Property: From Confrontation to Negotiation’ report (Spicy IP)

Distinctive + generic = pharma brand: Times article ‘How drug companies try to get inside your head’ (Spicy IP) (IPKat)

Austria: Supplementary protection certificates in Austria (The SPC blog)

China: Roger Bate determines China’s lethal counterfeit drugs pattern (IP Dragon)

France: Several ongoing cases before the Cour d’Appel de Paris regarding appeals to decisions by the Institut National de la Propriété Intellectuelle rejecting SPC applications based on ‘same previously market authorised product’ (The SPC blog)

India: Ayurgenomics – Asia’s longstanding tradition of herbal treatments trickles into Western pharma (Spicy IP)

India: Open source drug discovery (OSDD) research programme launched by CSIR (Spicy IP)

India: Some more thoughts on Bayh-Dole (Spicy IP)

Israel: Gene sequences are now patentable in Israel (The IP Factor)

Japan: Proposal for reform to patent term extension (PTE) regime (The SPC blog)

United States: Carnegie Mellon: A key ruling for biotech patents (Law360)

United States: Biocare wins bid to drop AsymmetRx patent suit covering antibodies used to diagnose prostate cancer (Law360)

United States: FDA’s view on generic drug label carve-outs (Law360)

United States: Intellectual property and access can co-exist, US rightsholders say (Intellectual Property Watch)

United States: Invitrogen sues Oxford Biomed and Vanderbilt University over patent covering recombinant protein technology (Law360)

United States: Judge in Amgen v Roche finds that competition by follow-on biologic will likely not lead to reduction in price, and might result in price increase (Holman’s Biotech IP Blog)

United States: Nature Biotechnology study finds declining litigation rates for DNA-based patents (Patent Docs)

United States: ‘Non-patent exclusivity and 180-day exclusivity forfeiture’ presentation slides from ACI’s FDA Boot Camp conference (Orange Book Blog)

United States: Plaintiffs move to settle antitrust action alleging Hoffman-La Roche and others exploited a patent useful in analysing DNA samples (Law360)

Pharma & Biotech – Products

Actonel (Risedronic acid) – US: Proctor & Gamble assert three patents against Teva over generic Actonel (Law360)

Alavert (Loratadine) – US: Walgreen seeks to overturn administrative ruling finding Wal-Vert mark confusingly similar to Wyeth’s Alavert (Law360) (The TTABlog)

Boniva (Ibandronic acid): Hoffmann-La Roche files amended complaints against Teva Pharmaceuticals of infringing patents related to osteoporosis drug (Law360)

Crestor (Rosuvastatin) – US: Teva accuses AstraZeneca of infringing its Crestor patent (Law360)

Enbrel (Etanercept) – US: Amgen secures favourable summary judgment ruling in Ariad case; judge allows Ariad to appeal case (Law360) (Law360)

Gemzar (Gemcitabine) – Australia: Don’t need quality patent information? Think again…:Interpharma Pty Ltd v Commisioner of Patents (GenericsWeb)

Gemzar (Gemcitabine) – US: Eli Lilly sues Teva for patent infringement and seek declaratory judgment (The IP Factor) (Law360)

Glivec (Imatinib) – India: Supreme Court appoints Dr Chakraborty as technical member on IPAB panel hearing Glivec appeal (Spicy IP)

Jeevani (Arogyapacha) – India: Recent developments in the Arogypacha case (Spicy IP)

Miralax (Polyethylene glycol) – US: ‘Advice of scientist’ defense to Walker Process: Braintree v Schwarz Pharma (PATracer)

Mircera (Methoxy polyethylene glycol-epoetin beta) – US: Trial judge grants permanent injunction in case relating to recombinant erythropoietin (EPO) patent: Amgen v F Hoffmann-LaRoche: (Hal Wegner) (Holman’s Biotech IP Blog) (Patent Docs) (Patent Docs) (Law360)

Oscion/Triaz (Benzoyl peroxide) – US: Federal Circuit affirms dismissal of Prasco’s declaratory judgment suit against Medicis (Orange Book Blog)

Oxytrol (Oxybutynin ) – US: Watson notified of Oxytrol patent challenge (Philip Brooks’ Patent Infringement Updates)

Pegasys (Pegylated interferon alfa-2a) – India: Pegasys patent hearing begins (Spicy IP)

Rilutek (Riluzole) – US: Prior art must enable a skilled artisan to make the invention without undue experimentation: Impax Labs v Aventis Pharmaceuticals (Patent Docs) (Hal Wegner) (Patent Prospector) (Law360) (Patently-O)

Seroquel (Quetiapine) – US: AstraZeneca sues Accord Healthcare over generic Seroquel (Law360)

Sutent (Sunitinib) – India: Natco withdraws ‘Doha’ compulsory licence application in respect of Roche’s ‘Tarceva’ and Pfizer’s ‘Sutent’ (Patent Circle) (Spicy IP)

Tarceva (Erlotinib) – India: Natco withdraws ‘Doha’ compulsory licence application in repect of Roche’s ‘Tarceva’ and Pfizer’s ‘Sutent’ (Patent Circle) (Spicy IP)

TriCor (Fenofibrate) -US: Court will not hear claims Abbott Laboratories and Fournier Industrie et Sante deceived the Patent Office but will hear claims the companies filed baseless patent litigation to keep out generic competition (Law360)

Ultracet (Tramadol hydrochloride and Acetaminophen) – US: Generic Ultracet clears another patent hurdle: Ortho-McNeil v Kali (PATracer)

Valcyte (Valganciclovir) – India: Cipla to reply to Mumbai High Court in two weeks in patent infringement suit filed by Hoffmann-La-Roche (Patent Circle)

Xavin (Budesonide) – Global: OPKO acquires worldwide opthalmic rights to Teva’s Budesonide for inflammatory and allergic ocular conditions (SmartBrief)

Xopenex (Levosalbutamol) – US: Sepracor’s wilfulness claim struck in suit over Xopenex (Law360)

Zovirax (Aciclovir) – EU: AG Sharpston delivers opinion in trade mark infringement and pharmaceutical repackaging case: Wellcome Foundation Ltd v Paranova Pharmazeutika Handels GmbH (IPKat)